INTRODUCTION
The accurate prediction of hepatic clearance (CL H ) is an essential step in the identification of new chemical entities as drug candidates and in the estimation of human pharmacokinetics. CL H is determined by hepatic metabolism and biliary excretion. Reasonable prediction accuracy of CL H for compounds with high hepatic metabolism has been achieved by interspecies scaling and in vitro-in vivo extrapolation (IVIVE) from liver microsome or hepatocyte incubations. 2 In vitro-in vivo extrapolation from sandwichcultured hepatocytes (SCHs) is an approach to estimating biliary clearance (CL b ); however, low bile or blood flow and the variable expression levels of influx and/or efflux transporters can result in a 10-100-fold underestimation of CL b in IVIVE from SCH. 3, 4 Several reports reveal that the expression levels and activities of influx transporters such as Oatps, Ntcp, and Oct1 in rat hepatocytes were consistently and considerably reduced in the SCH model, [5] [6] [7] thus leading to underestimation of CL b . Additionally, the expression levels of canalicular efflux transporters are inconsistent between different laboratories. Li et al. 8 reported a 40% decrease in the bile salt export pump (Bsep) protein level, a 50% decrease in the multidrugresistance-related protein 2 (Mrp2) protein level, and JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 102, NO. 8, AUGUST 2013 a fivefold increase in the breast cancer resistance protein (Bcrp) level in sandwich-cultured rat hepatocytes (SCRHs) over 5 days in culture. Tchaparian et al. 7 observed dramatically increased protein levels of P-glycoprotein (P-gp), Bcrp, and Mrp 1, 2, 3, and 4 over 4 days in culture. In Borlak's report, 5 the expression levels of canalicular transporters P-gp and Mrp2 were similar to those determined in vivo.
One strategy for correcting the underestimation of CL b is to incorporate a universal empirical correction factor determined by correlating CL b predicted from SCRHs with the observed in vivo CL b . 9 A reasonable correlation between CL b predicted by SCRHs and in vivo CL b was observed among drugs that undergo similar uptake (Organic anion transporting polypeptides, Oatps) and efflux mechanisms (Mrp2 or Bcrp) such as angiotensin II receptor blockers, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)reductase inhibitors, and $-lactam antibiotics. [9] [10] [11] On the contrary, for compounds in which different combinations of influx and efflux transporters are involved in the biliary excretion, or when passive diffusion is involved, the universal correction factor might not work. To address this issue, Li et al. 4 proposed using the ratio of the protein amount of canalicular efflux transporters (Mrp2, Bsep, and Bcrp) in rat liver to that in SCRH as a correction factor. Improved prediction accuracy was achieved by this method; however, this strategy ignored the decreased expression levels of sinusoidal influx transporters in SCRHs, which might seriously affect the predictability of the SCRH model.
In the current study, a universal correction factor and a series of correction factors based on the activities of both influx and efflux transporters were examined for IVIVE of CL b . A universal correction factor was estimated by linear regression analysis of 21 compounds in a training set. To determine whether transporter-specific correction factors can improve IVIVE, the compounds in the training set were divided into transporter-specific subgroups based on uptake and excretion mechanisms. Although both the universal correction factor and the transporterspecific correction factors provided reasonable CL b predictions when applied to the independent test set; the use of transporter-specific correction factors resulted in a greater improvement of prediction precision.
MATERIALS AND METHODS

Chemicals
Topotecan, benazeprilat, rosuvastatin, rosuvastatind6, candesartan, atorvastatin, olmesartan, deferasirox, temocaprilat, irinotecan, and octreotide acetate were purchased from Toronto Research Chemicals (North York, Ontario, Canada 
Metabolic Stability Assay
Cryopreserved rat hepatocytes (Celsis IVT, Baltimore, Maryland) were used for the hepatocyte stability assay. The cryopreserved hepatocytes were thawed in InVitroGRO TM HT (Celsis IVT, Baltimore, Maryland) medium and centrifuged at 100g for 10 min. Cells were resuspended in Dulbecco's Modified Eagle Medium (DMEM) (Gibco R , Grand Island, New York), and viability was assessed by the trypan blue exclusion method. Hepatocytes with viability greater than 80% were used in the study. The compounds (1 :M in DMEM) were incubated with hepatocytes (0.5 × 10 6 cells/mL) in a CO 2 incubator with 95% air/5% CO 2 at 37
• C and 95% humidity. At 0, 10, 30, and 60 min, aliquots of the incubation mixture were taken out and the reaction was quenched by adding two volumes of acetonitrile containing 100 nM of rosuvastatin-d6. The mixtures were then centrifuged at 2095g for 10 min to precipitate the protein. The supernatants were diluted with two volumes of water and transferred into a 96-well assay plate to measure the disappearance of parent compounds by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The predicted hepatic metabolic clearance (CL met ) was calculated using the following previously reported equation 2 :
where Q p represents the rat hepatic plasma flow rate (40 mL*min −1 *kg −1 ), CL int represents the intrinsic clearance, and f u represents the unbound fraction in rat plasma, which was collected from the literature (Table 1) .
Hepatocyte Culture
Sandwich-cultured rat hepatocytes (B-CLEAR R ), which were isolated from male Wistar rats and cultured in 24-well plates, were purchased from Qualyst, Inc. (Durham, North Carolina). Hepatocytes were cultured in the medium provided by Qualyst, Inc. at 37
• C in a humidified incubator with 95% air/5% CO 2 . Medium was changed daily. On day 4 after hepatocyte seeding, the SCRHs were subjected to accumulation studies. 
Accumulation Studies and Analysis
Accumulation studies were conducted as described previously. 10 Hepatocytes were rinsed twice and then preincubated for 10 min at 37
• C with 0.6mL of warmed Hank's balanced salt solution (HBSS) either containing Ca 2+ or not containing Ca 2+ to maintain or disrupt the tight junctions sealing bile canalicular networks, respectively. Subsequently, hepatocytes were incubated with the test compound (1 :M for [ 3 H]taurocholate and 10 :M for the other compounds) in standard HBSS for 10 min at 37
• C. After incubation, the dosing solution was aspirated from the cells, and uptake was stopped by washing the cells three times with ice-cold standard HBSS. For radiolabeled compound, cells were lysed with 0.5 mL of 0.5% Triton X-100 in phosphate-buffered saline (SigmaAldrich, St. Louis, Missouri). The samples were analyzed for compound concentrations by liquid scintillation counting. For other compounds, cells were lysed with 0.3 mL of 90% (v/v) methanol containing 100 ng/ mL of rosuvastatin-d6 (internal standard) and sonicated for 30 s with a sonic dismembrator (model 100; Thermo Fisher Scientific, Waltham, Massachusetts) and then transferred to a 96-well centrifugation filterplate (Corning Inc., Acton, Massachusetts). After centrifugation (2095g × 20 min), the filtrates were transferred to a 96-well plate and sealed for LC-MS/ MS analysis. Substrate accumulation was corrected for nonspecific binding by using Matrigel-precoated 24-well plates without cells. Because of incompatibility of the protein assay with methanol, the average protein concentration for standard HBSS or Ca 2+ -free HBSS incubations in the same liver preparation was used to normalize accumulation. Lysates were quantified by the bicinchoninic acid protein assay (Pierce Biotechnology, Inc., Rockford, Illinois) using bovine serum albumin as the reference standard, and accumulation was normalized to protein concentration.
LC-MS/MS Analysis
An Agilent 1100 HPLC system (Agilent Inc., Santa Clara, California) connected to an Applied Biosystems API 3000 triple quadrupole mass spectrometer with an electrospray ion source (Foster City, California) was used for sample analysis. A total of 20 :L of sample was injected into the LC-MS/MS. The flow rate of the mobile phases [aqueous phase, water with 0.1% formic acid (v/v) and 10 mM ammonium formate; organic phase, acetonitrile with 0.1% formic acid (v/ v)] was 0.3 mL/min. Isocratic or gradient elution was used to elute the various compounds from a Zorbax ODS C18 (50 × 2.1 mm 2 , 3 :m) column (Agilent Inc.). Rosuvastatin-d6 was used as an internal standard. The standard curve for each compound was individually established by using Matrigel-precoated 24-well plates with hepatocytes. 
Data Analysis
The concentration of compound in the medium was defined as the initial substrate concentration (1 or 10 :M) in the incubation medium. Intracellular volume was assumed to be 5.2 :L/mg protein. 
In vivo
where Q p represents the rat hepatic plasma flow rate (40 mL*min −1 *kg −1 ) 8 and f u represents the unbound fraction in rat plasma.
Average absolute fold error (AAFE) 1 was used to assess the prediction precision of various correction approaches. AAFE was calculated as following:
Data Set
Forty-one compounds, which were reported to undergo biliary excretion, were randomly assigned to a training set (n = 21) and a test set (n = 20 
RESULTS
Selection of Probe Substrates
The selection criteria for probe substrates in the training set included: rat in vivo CL b and rat plasma f u values available in literature; active hepatic uptake and/ or biliary excretion; and limited hepatic metabolism. To ensure limited hepatic metabolism, the metabolic stability of 18 compounds in the training set were assessed in suspended rat cryopreserved hepatocytes. As shown in Table S1 , IVIVE from cryopreserved rat hepatocyte incubation showed that all the 18 compounds were metabolically stable. The other three compounds (rosuvastatin, fexofenadine, and olmesartan) in the training set have been previously reported to be stable in rat liver microsome and hepatocyte incubations.
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Determination of Universal Correction Factor
In vitro apparent CL b values based on compound concentration in the medium were calculated using Eq. 2 and scaled to kilograms of body weight (CL b, app ; mL*min −1 *kg −1 ) ( Table 1 for training set and Table 2 for test set). The predicted CL b, app was obtained from CL b, app using Eq. 4 (Tables 1 and 2) . A reasonable linear correlation (R 2 = 0.875) between the predicted CL b, app and observed in vivo CL b was observed for 21 compounds in the training set (Fig. 1a) , although the observed in vivo CL b values were on average 10.2-fold higher than the predicted values. Similarly, a linear correlation (R 2 = 0.746) between predicted CL b, app and observed in vivo CL b was observed for 20 compounds in the independent test set (Fig. 1b) , and the predicted CL b, app values were underestimated by an average of 11.0-fold.
The slope (10.2) of the linear correlation equation obtained from the training set was used as a universal correction factor to correct the underestimation of CL b . The correction factor was applied to both the training and test sets (Tables 1 and 2) , and the corrected CL b values were plotted against the observed in vivo CL b for the training (squares) and test (triangles) sets (Fig. 2) . A total of seven out of 21 compounds in the training set (highlighted in bold font in Table 1 ) and seven out of 20 compounds in the test set (highlighted in bold font in Table 2 (Table 2) , both predicted and observed values consistently indicated that the compounds were in the low CL b category (CL b < 12 mL*min −1 *kg −1 ). Similar results were found in the training set (Table  1 ). These observations suggest that the SCRH model combined with a correction factor can be utilized to predict whether an unknown compound has low, moderate, or high CL b .
As a comparison, in vivo CL b was tentatively extrapolated from CL b, int, in vitro , which is based on the intracellular drug concentration in the SCRH model (Eq. 3). 99 CL b, int, in vitro (mL*min −1 *mg −1 of protein) was scaled to in vivo CL b (mL*min −1 *kg −1 ) using physiological parameters; however, no linear correlation between the predicted CL b and observed in vivo CL b was observed in the training set (Table  S2 and Fig. S1 ). The linear regression R 2 value was 0.235. 
Determination of Transporter-Specific Correction Factors
As the variable (in vitro vs. in vivo) expression levels of hepatic influx and efflux transporters in the SCRH model lead to inaccuracies in predictions, transporterspecific correction factors were introduced into IVIVE to determine whether these corrections would improve the model. The major influx and efflux transporters involved in the active transport of substrates are listed in Tables 1 and 2 . The transporters in parentheses are minor transporters responsible for uptake and efflux. Compounds in the training set were selected for linear regression analysis by the following criteria: predicted CL b, app × 10.2 was greater than 3.5 mL*min −1 *kg −1 ; both uptake and efflux mechanisms are known; and at least two compounds were available in each group for linear regression. Hence, seven compounds in the training set were divided into an Oatps/Mrp2 group (n = 5) and a diffusion/Pgp group (n = 2). Linear correlation analysis among the five Oatps/Mrp2 substrates (Fig. 3a, squares) and the two diffusion/P-gp substrates (Fig. 3b, squares) in the training set gave Oatps/Mrp2-specific and diffusion/P-gp-specific correction factors (11.8 and 8.0, respectively).
Application of Transporter-Specific Correction Factors to Test and Training Sets
The two transporter-specific correction factors were appropriately applied to five Oatps/Mrp2 substrates and two diffusion/P-gp substrates in the test set (Table 3 ; Fig. 3, triangles) . The CL b values of the other 13 compounds in the test set were not corrected because either the corresponding correction factors were not available or the predicted CL b, app × 10.2 was 3.5 mL*min corrections (Fig. 4a, triangles) . All seven predictions for the test set compounds were within 1.5-fold error of the observed in vivo CL b . When the transporterspecific correction factors were appropriately applied to seven compounds in the training set (five Oatps/ Mrp2 substrates and two diffusion/P-gp substrates), six predictions fell within 1.5-fold error, whereas the predicted CL b of enalaprilat (7.35 mL*min −1 *kg −1 ) was more than twofold of the observed CL b (2.96 ± 0.32 mL*min −1 *kg −1 ) 18 (Fig. 4a, squares) . As a comparison, the general correction factor (10.2) was applied to the seven test set compounds and seven training set compounds ( Table 3 ). The observed in vivo CL b values were plotted against the predicted CL b values based on the correction factor of 10.2 (Fig. 4b, triangles for the test set and squares for the training set). The results show that the transporterspecific corrections improve prediction precision compared with the universal correction. For the seven compounds in the test set, the AAFE of predictions decreased from 1.24 (universal correction factor 10.2) to 1.11 (transporter-specific correction factors). For the seven compounds in the training set, the AAFE of predictions decreased from 1.31 (universal correction factor 10.2) to 1.21 (transporter-specific correction factors).
DISCUSSION
Biliary excretion is an important elimination mechanism of xenobiotics and their metabolites. Although SCH models have been utilized to estimate human and rat CL b for more than a decade, 99 ,100 the accurate prediction of CL b is still a challenging task. For drugs that undergo similar uptake and efflux mechanisms, such as angiotensin II receptor blockers, HMG-CoA reductase inhibitors, and $-lactam antibiotics, the CL b values predicted by SCHs are linearly correlated with observed in vivo CL b . 9, 11, 100, 97 However, CL b can be underestimated by 10-100-fold because of limited dynamic bile and blood flow and time-dependent alterations in the protein concentration of influx and efflux transporters. 3, 4 To address this underestimation, Li et al. 4 incorporated ratios of efflux transporter protein levels in rat liver to those in SCRHs into IVIVE as correction factors. Similarly, in the present study, compounds were divided into subgroups based on uptake and efflux mechanisms. We utilized the ratio of the active transport activity in rat liver and to that in SCRH as a transporter-specific correction factor for each subgroup. Transporter-based correction factors were obtained by linear correlation analysis between the observed in vivo CL b and predicted CL b, app of training set compounds that undergo the same influx and efflux mechanisms. Compared with correction factors based on the protein amount of efflux transporters only, the transporter-based correction factors in this study address the variable activities of both influx and efflux transporters in the SCRH model. The predictability of the correction factors was examined using an independent test set in which the in vitro and in vivo data were collected from the literature. The results showed that both the prediction accuracy and precision were improved by incorporating the transporter-based correction factors into IVIVE.
In this study, a linear correlation between predicted CL b, app from the SCRH model and in vivo CL b was observed in both a training and an independent test set ( Figs. 1a and 1b) , although different uptake and efflux mechanisms were involved in the biliary excretion of these compounds (Tables 1 and 2 ). The lower coefficient of determination in the literature-based test set (R 2 = 0.746) than in the training set (R 2 = 0.875) is likely because of interbatch and interlaboratory variations. The underestimation of CL b, app between the training set (10.2-fold) and the independent test set (11.0-fold) was consistent, suggesting that the underestimation of CL b can be corrected by an empirical correction factor. Consistent with the previous reports, 11, 60, 101 normalization with f u in rat plasma in Eq. 4 significantly improved the linear correlation between the predicted CL b, app and observed in vivo CL b but caused further underestimation of CL b . When f u was not incorporated into Eq. 4, the predicted CL b was closer to in vivo CL b but the correlation coefficient of determination was much lower (data not shown). The value of 3.5 mL/min/kg for predicted CL b, app × 10.2 was found to be a cutoff level for accurate prediction of CL b in the SCRH model. The CL b of compounds with high CL b, app, in vitro and/or low plasma protein binding are more likely to be accurately predicted by the SCRH model. For compounds with low CL b, app, in vitro and/or high plasma protein binding, CL b might be underestimated by up to 30-fold (e.g., candesartan) or overestimated by up to 14-fold (e.g., lomefloxacin), although both predicted and observed CL b consistently suggested low biliary excretion for these compounds (CL b < 12 mL*min −1 *kg −1 ). The poor predictions could be a result of many factors. First, a measurement error in in vitro and in vivo CL b may affect the prediction accuracy, especially for compounds with low biliary excretion. Second, prediction errors might be caused by variable transporter activities in the SCRH model. For example, decreased sinusoidal influx transporter activities in SCRH might have caused the underprediction of CL b of octreotide, cefoperazone, cephradine, and cefmetazole. A previous report showed that CL b values of cefoperazone and cefmetazole were consistently underestimated by more than 10-fold, even though the Mrp2 protein concentration ratio between rat liver and SCRH was incorporated into IVIVE as a correction factor. 4 On the contrary, increased or relatively unchanged canalicular efflux transporter activities likely resulted in the overprediction of CL b for lomefloxacin, rifampicin, and dexamethasone, especially when the universal correction factor 10.2 was incorporated into IVIVE. Third, compounds with high plasma protein binding, not surprisingly, exhibit poor predictions of CL b . When f u is 0.01 or less (e.g., indomethacin, deferasirox, olmesartan, candesartan, and valsartan), normalization with f u (Eq. 4) is expected to cause significant prediction errors because of potential measurement errors in f u . Fourth, to achieve good responses on LC-MS/MS, most compounds, especially those with low hepatocyte uptake, were incubated at 10 :M in protein-free medium. For high-protein-binding compounds, the free concentration in the medium was much higher than the plasmafree drug concentrations in rats used for in vivo CL b measurement. The high concentration in the medium might partially saturate influx and/or efflux transporters in SCRHs, especially for compounds with low CL b, app, in vitro and a low Michaelis constant (K m ), thus resulting in underprediction of CL b (e.g., deferasirox, olmesartan, candesartan, and valsartan). If a very sensitive assay is available for compound quantitation, the prediction errors caused by high protein binding might be reduced by adding plasma protein to the incubation medium 35 or preparing the dosing solution in rat serum 102 for which normalization with f u is not required. It is noteworthy to mention that the addition of serum proteins to incubation medium did not remarkably change hepatocyte uptake of some lipophilic compounds with very high protein binding. 35 For these lipophilic compounds, serum proteins in culture medium serve as a drug solubilizer. The protein-bound drug might be transferred to hepatocyte cell membranes during protein-hepatocyte interaction, and the serum proteins facilitate drug uptake. This observation might explain the underestimation of CL b for very high-protein-binding drugs such as olmesartan and candesartan in the current study where f u correction was incorporated (Eq. 4).
Most SCRH studies are designed to determine CL b, app, in vitro on the basis of compound concentration in medium (Eq. 2), and then the predicted CL b, app is correlated with the observed in vivo CL b, app on the basis of compound concentration in rat plasma. Recently, Nakakariya et al. 60 reported IVIVE between CL b, int, in vitro and in vivo intrinsic CL b , which are based on compound concentrations in hepatocytes in the SCRH model (Eq. 3) and in liver tissue, respectively. In the SCRH model, the expression levels of sinusoidal influx transporters considerably decrease, whereas the protein expression of canalicular efflux transporters is relatively maintained during culture. Theoretically, IVIVE from CL b, int, in vitro values that reflect only canalicular efflux processes, should, therefore, be less susceptible to the variable expression of influx transporters. 60 Unfortunately, compound concentrations in rat liver were not available, and so in vivo intrinsic CL b values were unable to be determined in the current study. We, therefore, tentatively plotted the CL b extrapolated from CL b, int, in vitro and the observed in vivo CL b . A very poor correlation between in vivo CL b, app and CL b, int, in vitro was observed (Table S2 and Fig. S1 ). The CL b, int, in vitro only takes into account the canalicular efflux of a compound. However, in vivo CL b is a function of both the basolateral uptake and canalicular efflux. Therefore, a correlation would be expected only in cases where the canalicular efflux was the rate-limiting step.
Two uptake and efflux mechanism-based factors were obtained by linear correlation analysis between predicted CL b, app and observed in vivo CL b . The Oatps/Mrp2-specific factor (11.8) was higher than the universal factor (10.2), which might be explained by the decreased expression of Oatps in the SCRH model. The low value of the diffusion/P-gp-specific factor (8.0) was likely due to the unchanged or increased expression of P-gp in the SCRH model. Transporter expression variability between batches of SCRHs might limit the successful application of transporterbased corrections. Previous transporter quantitation studies 7, 8 consistently revealed that the changes in transporter expression and activities were mainly dependent on SCRH culture time. A dramatic decrease or increase in transporter expression occurred during 0-72 h after cell seeding. On day 4 and day 5 after cell seeding, further changes in transporter expression were relatively limited. In this study and the studies in the literature, the incubation of compounds with SCRHs was usually conducted on day 4 and day 5 after cell seeding, which might explain the comparable transporter activities among SCRH models used for the training set and test set compounds. Because of the time-sensitive changes in transporter expression in the SCRH model, a consistent culture time is highly recommended.
The transporter-based correction approach for CL b predictions requires an understanding of the major uptake and efflux mechanisms undergone by the drug candidate, which are usually not available at the early stage of drug development. In the absence of this information, the universal correction factor gave reasonable CL b predictions when the predicted CL b was greater than 3.5 mL/min/kg. For compounds with low in vivo CL b , the SCRH model combined with the universal correction factor could not quantitatively estimate absolute values of CL b , but it could qualitatively assign compounds to low, moderate, and high CL b categories.
CONCLUSIONS
In this study, we demonstrated that both the universal correction factor and transporter-based correction factors provide reasonable corrections of CL b , which are usually underestimated by the SCRH model. Transporter-based correction factors improved predictions compared with a universal correction factor. Considering the complicated hepatobiliary clearance processes of hepatic uptake, sinusoidal efflux, metabolism, and canalicular efflux, this transporterbased corrected IVIVE method provides excellent predictions of rat CL b .
